David V. Jobes
Founder at Mid-Atlantic BioTherapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jean-Pierre Gagnon | M | - |
Mid-Atlantic BioTherapeutics, Inc.
 Mid-Atlantic BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mid-Atlantic BioTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. The company was founded by David Horn, David Jobes, and Jean-Pierre Gagnon in 2011 and is headquartered in Doylestown, PA. | 13 years |
| David Horn | M | - |
Mid-Atlantic BioTherapeutics, Inc.
Mid-Atlantic BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mid-Atlantic BioTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. The company was founded by David Horn, David Jobes, and Jean-Pierre Gagnon in 2011 and is headquartered in Doylestown, PA. | 13 years |
| Michael J. Goldblatt | M | - |
Mid-Atlantic BioTherapeutics, Inc.
Mid-Atlantic BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mid-Atlantic BioTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. The company was founded by David Horn, David Jobes, and Jean-Pierre Gagnon in 2011 and is headquartered in Doylestown, PA. | - |
| Julian Chick | M | - |
Mid-Atlantic BioTherapeutics, Inc.
Mid-Atlantic BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mid-Atlantic BioTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. The company was founded by David Horn, David Jobes, and Jean-Pierre Gagnon in 2011 and is headquartered in Doylestown, PA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Elena Viboch | F | - |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 5 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David V. Jobes
- Personal Network
